$LGND
LIGAND PHARMACEUTICALS INC

2017 Q1 Form 10-Q Financial Statement

#000088616317000055 Filed on May 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $29.27M $29.65M
YoY Change -1.29% 103.04%
Cost Of Revenue $341.0K $955.0K
YoY Change -64.29% -11.08%
Gross Profit $28.93M $28.69M
YoY Change 0.81% 112.1%
Gross Profit Margin 98.83% 96.78%
Selling, General & Admin $7.320M $6.830M
YoY Change 7.17% 14.02%
% of Gross Profit 25.31% 23.8%
Research & Development $8.673M $4.004M
YoY Change 116.61% 18.88%
% of Gross Profit 29.98% 13.95%
Depreciation & Amortization $2.979M $2.575M
YoY Change 15.69% 296.15%
% of Gross Profit 10.3% 8.97%
Operating Expenses $8.673M $4.004M
YoY Change 116.61% 18.88%
Operating Profit $10.22M $15.10M
YoY Change -32.33% 350.76%
Interest Expense $2.941M $3.005M
YoY Change -2.13% 1.08%
% of Operating Profit 28.79% 19.91%
Other Income/Expense, Net -$4.023M -$5.525M
YoY Change -27.19% 61.41%
Pretax Income $6.193M $9.571M
YoY Change -35.29% -13033.78%
Income Tax $10.03M $3.694M
% Of Pretax Income 162.01% 38.6%
Net Earnings $45.28M $6.608M
YoY Change 585.21% 776.39%
Net Earnings / Revenue 154.71% 22.29%
Basic Earnings Per Share $2.13 $0.32
Diluted Earnings Per Share $1.83 $0.30
COMMON SHARES
Basic Shares Outstanding 21.21M shares 20.71M shares
Diluted Shares Outstanding 24.80M shares 22.28M shares

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.4M $113.2M
YoY Change 40.81% -36.12%
Cash & Equivalents $10.64M $31.29M
Short-Term Investments $148.7M $81.90M
Other Short-Term Assets $641.0K $1.562M
YoY Change -58.96% 68.68%
Inventory $7.629M $1.750M
Prepaid Expenses $1.087M
Receivables $7.100M $11.80M
Other Receivables $0.00 $5.200M
Total Short-Term Assets $174.7M $133.1M
YoY Change 31.3% -30.59%
LONG-TERM ASSETS
Property, Plant & Equipment $1.898M $567.0K
YoY Change 234.74% 28.86%
Goodwill $72.21M $73.00M
YoY Change -1.08% 496.48%
Intangibles $202.0M $212.8M
YoY Change -5.09% 324.55%
Long-Term Investments $7.262M $28.12M
YoY Change -74.17%
Other Assets $1.821M $70.00K
YoY Change 2501.43% -80.45%
Total Long-Term Assets $455.0M $480.4M
YoY Change -5.28% 571.76%
TOTAL ASSETS
Total Short-Term Assets $174.7M $133.1M
Total Long-Term Assets $455.0M $480.4M
Total Assets $629.7M $613.4M
YoY Change 2.65% 133.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.456M $2.688M
YoY Change 140.18% -63.88%
Accrued Expenses $4.680M $3.669M
YoY Change 27.56% -13.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $215.7M $600.0K
YoY Change 35850.0% -73.91%
Total Short-Term Liabilities $227.0M $12.24M
YoY Change 1754.53% -32.59%
LONG-TERM LIABILITIES
Long-Term Debt $26.90M $204.7M
YoY Change -86.86% 2.97%
Other Long-Term Liabilities $915.0K $446.0K
YoY Change 105.16% -42.82%
Total Long-Term Liabilities $915.0K $446.0K
YoY Change 105.16% -42.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $227.0M $12.24M
Total Long-Term Liabilities $915.0K $446.0K
Total Liabilities $230.9M $221.4M
YoY Change 4.33% -4.1%
SHAREHOLDERS EQUITY
Retained Earnings -$408.4M -$395.4M
YoY Change 3.29% -39.96%
Common Stock $21.00K $21.00K
YoY Change 0.0% 5.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $371.8M $392.1M
YoY Change
Total Liabilities & Shareholders Equity $629.7M $613.4M
YoY Change 2.65% 133.05%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income $45.28M $6.608M
YoY Change 585.21% 776.39%
Depreciation, Depletion And Amortization $2.979M $2.575M
YoY Change 15.69% 296.15%
Cash From Operating Activities $19.22M $13.11M
YoY Change 46.59% 73.03%
INVESTING ACTIVITIES
Capital Expenditures $87.00K $238.0K
YoY Change -63.45% 2280.0%
Acquisitions $0.00 $92.86M
YoY Change -100.0%
Other Investing Activities $87.00K -$79.50M
YoY Change -100.11% 2739.29%
Cash From Investing Activities -$25.67M -$79.76M
YoY Change -67.82% 2751.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $502.0K
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$1.667M $511.0K
YoY Change -426.22% -34.57%
NET CHANGE
Cash From Operating Activities $19.22M $13.11M
Cash From Investing Activities -$25.67M -$79.76M
Cash From Financing Activities -$1.667M $511.0K
Net Change In Cash -$8.111M -$66.14M
YoY Change -87.74% -1288.84%
FREE CASH FLOW
Cash From Operating Activities $19.22M $13.11M
Capital Expenditures $87.00K $238.0K
Free Cash Flow $19.14M $12.88M
YoY Change 48.63% 70.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000886163
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20996049 shares
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
LIGAND PHARMACEUTICALS INC
CY2016Q1 lgnd Accrued Inventory Purchases
AccruedInventoryPurchases
600000 USD
CY2017Q1 lgnd Accrued Inventory Purchases
AccruedInventoryPurchases
3909000 USD
CY2016Q1 lgnd Collaborative Research And Development And Other Revenues
CollaborativeResearchAndDevelopmentAndOtherRevenues
9917000 USD
CY2017Q1 lgnd Collaborative Research And Development And Other Revenues
CollaborativeResearchAndDevelopmentAndOtherRevenues
3916000 USD
CY2016Q4 lgnd Commercial License Rights
CommercialLicenseRights
25821000 USD
CY2017Q1 lgnd Commercial License Rights
CommercialLicenseRights
25630000 USD
CY2016Q4 lgnd Current Portion Of Liability For Contingent Value Rights
CurrentPortionOfLiabilityForContingentValueRights
5088000 USD
CY2017Q1 lgnd Current Portion Of Liability For Contingent Value Rights
CurrentPortionOfLiabilityForContingentValueRights
111000 USD
CY2017Q1 lgnd Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount
900000 USD
CY2016Q1 lgnd Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant
IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant
-15000 USD
CY2017Q1 lgnd Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant
IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant
76000 USD
CY2017Q1 lgnd Non Cash Change In Estimated Fair Value Of Contingent Value Rights
NonCashChangeInEstimatedFairValueOfContingentValueRights
-140000 USD
CY2017Q1 lgnd Note Receivable Interestand Principal Reductionper Dollarof Value
NoteReceivableInterestandPrincipalReductionperDollarofValue
0.50
CY2016Q1 lgnd Payments To Contingent Value Right Holders
PaymentsToContingentValueRightHolders
5446000 USD
CY2017Q1 lgnd Payments To Contingent Value Right Holders
PaymentsToContingentValueRightHolders
4998000 USD
CY2017Q1 lgnd Working Capital Deficit
WorkingCapitalDeficit
52300000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2734000 USD
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6456000 USD
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-320000 USD
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
46000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6397000 USD
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4680000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
829000 USD
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
799000 USD
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
942000 USD
CY2017Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
989000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2743000 USD
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3105000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
769653000 USD
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
777102000 USD
CY2016Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
4118000 USD
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
6045000 USD
CY2016Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2668000 USD
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
120758000 USD
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
146633000 USD
CY2016Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High
BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
-1306000 USD
CY2017Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2838000 USD
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3493425 shares
CY2017Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High
BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
-140000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97428000 USD
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3711067 shares
CY2016Q4 us-gaap Assets
Assets
601585000 USD
CY2017Q1 us-gaap Assets
Assets
629723000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
163053000 USD
CY2017Q1 us-gaap Assets Current
AssetsCurrent
174701000 USD
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
122296000 USD
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2016Q4 lgnd Liability For Contingent Value Rights
LiabilityForContingentValueRights
2916000 USD
CY2017Q1 lgnd Liability For Contingent Value Rights
LiabilityForContingentValueRights
3035000 USD
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
148733000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1564000 USD
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2139000 USD
CY2016Q1 lgnd Non Cash Change In Estimated Fair Value Of Contingent Value Rights
NonCashChangeInEstimatedFairValueOfContingentValueRights
-1306000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000 USD
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
39000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31293000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18752000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10641000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-66135000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8111000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
33333333 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
33333333 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20909301 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20996049 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20909301 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20996049 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
21000 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
21000 USD
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5274000 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5441000 USD
CY2016Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
212910000 USD
CY2017Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
215748000 USD
CY2016Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
955000 USD
CY2017Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
341000 USD
CY2016Q1 us-gaap Cost Of Services Amortization
CostOfServicesAmortization
2524000 USD
CY2017Q1 us-gaap Cost Of Services Amortization
CostOfServicesAmortization
2715000 USD
CY2016Q4 us-gaap Debt Instrument Convertible Carrying Amount Of The Equity Component
DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
29563000 USD
CY2017Q1 us-gaap Debt Instrument Convertible Carrying Amount Of The Equity Component
DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
26948000 USD
CY2016 us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days
DebtInstrumentConvertibleThresholdConsecutiveTradingDays
P50D
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
123891000 USD
CY2017Q1 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
141007000 USD
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2575000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2979000 USD
CY2016Q1 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
1139000 USD
CY2017Q1 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
0 USD
CY2016Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
731000 USD
CY2017Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
0 USD
CY2016Q1 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
408000 USD
CY2017Q1 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
0 USD
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2016Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.39
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.18
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2603000 USD
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1356000 USD
CY2016Q4 us-gaap Equity Method Investments
EquityMethodInvestments
8345000 USD
CY2017Q1 us-gaap Equity Method Investments
EquityMethodInvestments
7262000 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7069000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7322000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
5877000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
5079000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.28
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.24
CY2016Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.26
CY2016Q4 us-gaap Goodwill
Goodwill
72207000 USD
CY2017Q1 us-gaap Goodwill
Goodwill
72207000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
9571000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
6193000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.22
CY2016Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.04
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
CY2016Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.03
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2016Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1605000 USD
CY2017Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1083000 USD
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3694000 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1114000 USD
CY2016Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
CY2017Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
96000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4302000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1963000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5604000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7643000 USD
CY2016Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-4101000 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-1018000 USD
CY2016Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-853000 USD
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1197000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-745000 USD
CY2016Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
749736 shares
CY2017Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
941308 shares
CY2016Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
759581 shares
CY2017Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
954509 shares
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
204705000 USD
CY2017Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
201990000 USD
CY2016Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
276912000 USD
CY2017Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
274197000 USD
CY2016Q1 us-gaap Interest Expense
InterestExpense
3005000 USD
CY2017Q1 us-gaap Interest Expense
InterestExpense
2941000 USD
CY2016Q1 us-gaap Interest Paid
InterestPaid
919000 USD
CY2017Q1 us-gaap Interest Paid
InterestPaid
919000 USD
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
899000 USD
CY2017Q1 us-gaap Interest Payable Current
InterestPayableCurrent
890000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
1923000 USD
CY2017Q1 us-gaap Liabilities
Liabilities
230945000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
601585000 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
629723000 USD
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
226995000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
227129000 USD
CY2017Q1 us-gaap Inventory Net
InventoryNet
7629000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
230732000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
511000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1667000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-79760000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30666000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13114000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
24222000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
6608000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
5079000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5525000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4023000 USD
CY2016Q4 us-gaap Notes And Loans Receivable Gross Current
NotesAndLoansReceivableGrossCurrent
3207000 USD
CY2017Q1 us-gaap Notes And Loans Receivable Gross Current
NotesAndLoansReceivableGrossCurrent
0 USD
CY2016Q4 us-gaap Notes And Loans Receivable Gross Noncurrent
NotesAndLoansReceivableGrossNoncurrent
0 USD
CY2017Q1 us-gaap Notes And Loans Receivable Gross Noncurrent
NotesAndLoansReceivableGrossNoncurrent
3207000 USD
CY2016Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14552000 USD
CY2017Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
19051000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
15096000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
10216000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1124000 USD
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
646000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2175000 USD
CY2017Q1 us-gaap Other Assets Current
OtherAssetsCurrent
641000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1744000 USD
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1821000 USD
CY2016Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1098000 USD
CY2017Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-66000 USD
CY2017Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
CY2016Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
236000 USD
CY2017Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-428000 USD
CY2017Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
-202000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
687000 USD
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
915000 USD
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
391000 USD
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
141000 USD
CY2016Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-28000 USD
CY2017Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 USD
CY2016Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
502000 USD
CY2016Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
CY2017Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
238000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
87000 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.07
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
17.42
CY2017Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2022000 USD
CY2016Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
92855000 USD
CY2016Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
49892000 USD
CY2017Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
73352000 USD
CY2016Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
48401000 USD
CY2017Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
30052000 USD
CY2016Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
20270000 USD
CY2017Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
17719000 USD
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1013000 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
355000 USD
CY2016Q1 us-gaap Profit Loss
ProfitLoss
6608000 USD
CY2017Q1 us-gaap Profit Loss
ProfitLoss
5079000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1819000 USD
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1898000 USD
CY2016Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
406000 USD
CY2017Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
66000 USD
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
14700000 USD
CY2017Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
7057000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4004000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8673000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-431127000 USD
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408398000 USD
CY2016Q1 us-gaap Revenues
Revenues
29648000 USD
CY2017Q1 us-gaap Revenues
Revenues
29267000 USD
CY2016Q1 us-gaap Royalty Revenue
RoyaltyRevenue
14390000 USD
CY2017Q1 us-gaap Royalty Revenue
RoyaltyRevenue
24230000 USD
CY2016Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
5341000 USD
CY2017Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1121000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4118000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6045000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.50
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.47
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1300000 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
33.06
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
180765 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1754275 shares
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.00
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
100.81
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1905628 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.12
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7M6D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10M24D
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
122296000 USD
CY2017Q1 us-gaap Short Term Investments
ShortTermInvestments
148733000 USD
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
29412 shares
CY2016Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
-77615000 USD
CY2017Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
0 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
341290000 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
371830000 USD
CY2016Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1834000 USD
CY2017Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-66000 USD
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22284000 shares
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22283979 shares
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23019189 shares
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23019000 shares
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20707926 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20937627 shares
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20708000 shares
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20938000 shares
CY2016Q1 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
66736 shares
CY2017Q1 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
185745 shares
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0000886163-17-000055-index-headers.html Edgar Link pending
0000886163-17-000055-index.html Edgar Link pending
0000886163-17-000055.txt Edgar Link pending
0000886163-17-000055-xbrl.zip Edgar Link pending
exhibit101.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lgnd-20170331.xml Edgar Link completed
lgnd-20170331.xsd Edgar Link pending
lgnd-20170331_cal.xml Edgar Link unprocessable
lgnd-20170331_def.xml Edgar Link unprocessable
lgnd-20170331_lab.xml Edgar Link unprocessable
lgnd-20170331_pre.xml Edgar Link unprocessable
lgnd-3311710q.htm Edgar Link pending
lgnd_33117exhibit311.htm Edgar Link pending
lgnd_33117exhibit312.htm Edgar Link pending
lgnd_33117exhibit321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending